3SBio

3SBio, established in 1993, is a prominent, fully-integrated biotechnology company operating within China's biopharmaceutical sector. The company focuses on developing and commercializing innovative treatments across critical therapeutic areas, including oncology, auto-immune diseases, nephrology, metabolic diseases, and dermatology. Its strategic positioning within the biotechnology industry leverages a robust pipeline of biopharmaceutical products, aiming to address significant unmet medical needs.

With a significant operational footprint, 3SBio employs between 5,000 - 10,000 employees, underscoring its substantial scale. The company's primary headquarters are situated in Shenyang, Liaoning, China, serving as the central hub for its extensive operations. As a pioneer in its field, 3SBio is dedicated to advancing scientific research and development, contributing to the growth and innovation within the Chinese biotechnology landscape. Meet 3SBio's team to understand the expertise driving its advancements.

Financially, 3SBio reported a revenue of $1.1B. The company has a history of strategic financial activities, including a significant stock issuance/offering event in May 2015 totaling $712 million. This financial backing supports its ongoing research, development, and market expansion efforts. 3SBio's commitment to innovation and its established presence in key therapeutic areas position it as a significant player in the biopharmaceutical market. Explore financial highlights for a deeper dive into its fiscal performance.